Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter
YouTube

75° Mostly Cloudy
- Broken Bow, NE (68822)
  Today
  
  Thunderstorms during the evening will give way to cloudy skies after midnight. Low near 65F. Winds SE at 10 to 15 mph. Chance of rain 70%..
  
  Tonight
  
  Thunderstorms during the evening will give way to cloudy skies after midnight. Low near 65F. Winds SE at 10 to 15 mph. Chance of rain 70%.
  
  Updated: September 17, 2026 @ 5:11 pm
- Full Forecast

Site search

Home
News
- Local News
Sports
Obituaries
Photos
Videos
e-Edition
Classifieds
- Legal Notices
Business Directory

Recent Quotes

View Full List

My Watchlist

Create Watchlist

Indicators

Dow Jones Industrial Average

Markets:

Overview

News

Currencies

International

Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

72.94 +2.81 (+4.01%)

Delayed Quote Updated: 2:53 PM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell' ↗

January 12, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified

Via Benzinga

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

January 11, 2024

Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced.

Via Chartmill

NASDAQ:EXEL is showing good growth, while it is not too expensive. ↗

December 21, 2023

Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

6 Analysts Have This to Say About Exelixis ↗

December 13, 2023

Via Benzinga

NASDAQ:EXEL, a growth stock which is not overvalued. ↗

November 29, 2023

Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.

Via Chartmill

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? ↗

January 08, 2024

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an

Via Benzinga

Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes ↗

January 08, 2024

Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.

Via Investor's Business Daily

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

January 07, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

January 02, 2024

From Exelixis, Inc.

Via Business Wire

Looking for growth without the hefty price tag? Consider NASDAQ:EXEL. ↗

November 06, 2023

EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.

Via Chartmill

Where Exelixis Stands With Analysts ↗

November 02, 2023

Via Benzinga

Earnings Outlook For Exelixis ↗

October 31, 2023

Via Benzinga

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

December 07, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

December 04, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

December 04, 2023

From Arcus Biosciences

Via Business Wire

Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment

November 29, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

November 21, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

November 10, 2023

From Exelixis, Inc.

Via Business Wire

Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures ↗

November 09, 2023

Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.

Via InvestorPlace

3 Biotech Stocks With the Strongest Clinical Pipelines ↗

November 08, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

Via InvestorPlace

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

Exelixis (EXEL) Q3 2023 Earnings Call Transcript ↗

November 02, 2023

EXEL earnings call for the period ending September 30, 2023.

Via The Motley Fool

Topics Earnings

Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 01, 2023

From Exelixis, Inc.

Via Business Wire

4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

October 28, 2023

Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.

Via The Motley Fool

Topics Stocks

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Why Exelixis Stock Is Trading Lower Today ↗

October 23, 2023

Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in

Via Benzinga

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

October 22, 2023

From Exelixis, Inc.

Via Business Wire

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

These three lesser-known biotech companies are profitable and growing revenue.

Via The Motley Fool

Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023

October 18, 2023

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Business
Entertainment
Local Events
Obituaries
Multimedia
Online Features

Services

Subscription Services
Pay Your Bill
Classifieds
Promote Your Event
Email Alerts
Place an Ad
Rack Locations
Search
Weather

custercountychief.com
311 South 10th Avenue
Broken Bow, NE 68822
Phone: 308-872-2471
Email: publisher@custercountychief.com

Facebook
Twitter
YouTube

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Broken Bow, NE (68822)

Today

Tonight

Exelixis, Inc. - Common Stock (NQ:EXEL)

All News about Exelixis, Inc. - Common Stock

Sections

Services

Follow Us